At initial presentation, AML patients harboring mutated STAG2 were significantly older (58 years vs. 55 years, p = 0.023) and had lower WBC (median 5.4 × 109/l vs. 20.7 × 109/l, p < 0.001), PBB (20.0% vs. 41.0%, p < 0.001), BMB (48.3% vs. 63.5%, p < 0.001) and LDH (median 342 U/l vs. 450.8 U/l, p = 0.001). The gene discussed is STAG2; the disease is acute myeloid leukemia.